25255-56-5

Upstream product

• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 651729-70-3 methyl 2,2-dimethyl-3-phenoxypropanoate 
• 60520-17-4 toluenesulfonyl [⁽¹⁸⁾F]-fluoride 
• 1001335-23-4 3-(4-bromo-2-formyl-phenoxy)-2,2-dimethyl-propionic acid methyl ester 
• 651729-37-2 methyl 3-(3,5-dimethylphenyloxy)-2,2-dimethylpropionate 
• 25307-79-3 tert-butyl 2,2-dimethyl-3-(tosyloxy)propanoate 
• 1001335-67-6 3-(4-chloro-2-formyl-phenoxy)-2,2-dimethyl-propionic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of [18F]fluoro-pivalic acid: An improved PET imaging probe for the fatty acid synthesis pathway in tumours

[18F]Fluoro-pivalic acid ([18F]FPIA), an analogue of [18F]fluoroacetate bearing a dimethyl moiety on C-2, has been radiosynthesised and evaluated in vivo. [18F]FPIA has high tumour uptake and, unlike [18/s

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g, protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g, a cancer or a metabolic disease.

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING

The present invention pertains generally to the field of imaging compounds, and more specifically to certain 2,2-dialkyl radionuclide-labelled carboxylic acids suitable for PET, SPECT and/or DNP imaging. Also described are uses of such compounds in the im

Spiroindolinone Derivatives

There are provided compounds of the formula and pharmaceutically acceptable salts and esters and enantiomers thereof wherein W, X, X′, Y, V, V′, A, B and R are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.

SPIROINDOLINONE DERIVATIVES

There are provided compounds of the formula and pharmaceutically acceptable salts and esters thereof wherein W, V, X, Y, A, R and R' are as described herein. The compounds are useful as anticancer agents.

Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses

This invention relates to poly-substituted derivatives of the N-(benzyl)phenylacetamide type, pharmaceutical compositions comprising same, therapeutic uses thereof, more particularly in the fields of human and animal health. This invention also relates to a process for the preparation of such derivatives.

Process for preparing isomerically pure prodrugs of proton pump inhibitors

Synthetic methods for preparing isomerically pure N-arylsulfonyl derivatives of proton pump inhibitors which include a substituted benzimidazole nucleus are shown by the synthetic schemes and experimental description.

PRODRUGS OF PROTON PUMP INHIBITORS

Prodrugs of proton pump inhibitors of Formulas 1 through 4, (I-IV), where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.